AKT1 and Hyperglycemia: The serious toxicities of PI3K/AKT/mTOR inhibitors limit their clinical use and approval, including hyperglycemia, hyperlipidemia, bone marrow suppression, pneumonia, stomatitis, and hepatotoxicity [16].